Fort Myers-based NeoGenomics Inc. is growing again. The company, specializing in genetic testing for cancer, announced it has completed the acquisition of Genoptix Inc., a leading clinical oncology ...

Lab is located in same building as PPD® Laboratories’ Central Lab and will support Asia-Pacific oncology trials Fully integrated with PPD’s CRO capabilities, PPD Laboratories offers bioanalytical, ...

FT. MYERS, Fla., Oct. 23, 2018 (GLOBE NEWSWIRE) — NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a definitive ...

-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize ...

This time it's going to China. The Fort Myers-based laboratory — specializing in genetic testing for cancer — has announced plans to grow its global footprint with the addition of a research lab in ...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual ...

FORT MYERS, FL / ACCESSWIRE / October 13, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced plans to open a ...

NeoGenomics has laid the foundation for rebuilding itself. But it has a lot more work to do. That's the takeaway from the local company's second-quarter earnings call on Tuesday. The Fort Myers-based ...

Operating a network of CAP-accredited and CLIA-certified laboratories across the United States and United Kingdom, NeoGenomics (NASDAQ:NEO) provides specialized cancer diagnostic testing services, ...

The cancer genetics company reported full-year 2019 operating results, but that's probably not the reason for the decline. NeoGenomics reported full-year 2019 revenue of $408.8 million and adjusted ...